Researchers behind a small, unpublished US trial are urging caution after early data on a tightly controlled cannabis formulation and dementia-related agitation drew media attention. The study’s own authors are warning against treating the results as evidence that cannabis products help with dementia symptoms, stressing that what they tested has little in common with anything sold commercially.

The trial, known as LiBBY, gave 120 participants living with Alzheimer’s disease or other forms of dementia either a purified THC-CBD formulation or a placebo, under close clinical supervision, over twelve weeks. Researchers recorded a change in caregiver-reported agitation scores among some participants. But the study has not been peer reviewed or published, and the researchers themselves say that matters: unreviewed results are not the same as established evidence.

Not what’s on the shelf, and not a treatment recommendation

Clinical Nurse Practitioner Brigid Reynolds, who worked on the trial, was explicit that the formulation used was carefully manufactured and administered under close medical supervision, and that this bears no resemblance to over-the-counter THC and CBD products, which vary widely in composition and dosing and may be ineffective or even harmful. Researchers presenting the findings at the Alzheimer’s Association International Conference repeatedly stressed that the trial does not support the use of commercially available cannabis for dementia agitation, and that families should not read the coverage as a reason to seek out cannabis products for a loved one.

Why agitation is hard to manage, and why that makes hype dangerous

Doctors currently reach for medications such as morphine, Valium and Haldol to manage dementia-related agitation, and these drugs have shown limited effectiveness with side effects of their own. That gap is real, and it’s precisely why unproven or unregulated alternatives can gain traction quickly among desperate families, long before the evidence is actually there to support them. Agitation itself can show up as restlessness, aggression and emotional distress, taking a toll on patients and caregivers alike, which is exactly the kind of pressure that makes clear, cautious communication about early-stage research so important.

Ten medical centres across the country ran the LiBBY study visits in participants’ own homes, with caregivers rating agitation on a seven-point scale throughout. Researchers describe the early data as worth further study, not as a finding ready for clinical use, let alone something the public should act on. Any change in scores recorded during the trial happened only within a controlled, medically supervised setting, using a formulation not available to consumers, monitored by clinicians throughout.

One participant’s daughter, Laura, said her mother’s involvement in the trial gave her hope for future treatment options, even without knowing during the study whether her mother had received the medication or the placebo.

Researchers stress that far more work, including peer review and larger, replicated trials, is needed before any conclusions can be drawn about cannabis for dementia agitation. In the meantime, the message from the study’s own authors is unambiguous: this is not evidence that cannabis products are safe or effective, and unregulated products carry real risks that this trial does nothing to change.